11 completed, 2 not yet recruiting, 1 active not recruiting, 1 recruiting. 9 Phase 1, 3 Not applicable, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 7, Active not recruiting 1, Not yet recruiting 1 |
| Not applicable | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Dose 1: new trials by email Literature Review of Dose 1 trials Research Report on Dose 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet Dose 1, Dose 2 - Food Effect in Healthy Volunteers, Weight Management | Phase 1 | Not yet recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 72 | 2026-11-03 | 2026-11-13 |
| FXS6837 for the Treatment of IgAN Patients FXS6837 Dose 1, FXS6837 Dose 2, Placebo Capsule - IgAN | Phase 2 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 60 | 2026-03-31 | 2026-03-31 |
| Safety, Tolerability and Pharmacokinetics of ETD-001 Gel Dose 1, dose 2, dose 3 - Safety Issues | Phase 1 | Completed | Etern Therapeutics Wuxi Limited | 56 | 2026-03-16 | 2026-09-10 |
| Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234 AZD6234 - Renal Impairment | Phase 1 | Completed | AstraZeneca | 24 | 2025-02-24 | 2025-11-03 |
| Reach Through Equitable Implementation in Utah Clinic Level: AAC - SDOH, AAC - Tobacco, Non-Bundled, Bundled - Tobacco Use Cessation, Tobacco Use | Not applicable | Recruiting | University of Utah | 1560 | 2025-02-13 | 2025-03-18 |
| Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 AZD5004 - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 33 | 2024-12-19 | 2025-10-15 |
| A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 AZD5004 - Renal Impairment | Phase 1 | Completed | AstraZeneca | 16 | 2024-12-17 | 2025-06-08 |
| Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 AZD0780 - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 16 | 2024-08-08 | 2026-11-10 |
| Perioperative Methadone in Hip Fracture Patients Methadone (Dose1), Methadone (Dose 2), Methadone (Dose 3) - Methadone, Pain, Post Operative | Phase 4 | Completed | University of Southern Denmark | 31 | 2023-01-12 | 2023-04-18 |
| Vitamin D Levels Following Topical Application of Vitamin D Ointment Dose 1, Dose 2 - Vitamin D Deficiency | Phase 1 | Completed | University of Minnesota | 10 | 2016-03-01 | 2019-11-01 |
| Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) PXT3003 dose 1, PXT3003 dose 2, placebo - Charcot-Marie-Tooth Disease Type 1A | Phase 3 | Completed | Pharnext S.C.A. | 323 | 2015-12-01 | 2020-02-27 |
| Effects of Polyphenols Found in Pomegranate and Olives Food Supplements on Postprandial Blood Glucose in Vivo. Control (109 g white bread), Dose 1, Dose 2 - Hyperglycaemia | Not applicable | Completed | University of Leeds | 16 | 2015-06-01 | 2016-04-20 |
| Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) Dose 1, Dose 2, Dose 0 - Diabetes Prevention | Phase 1 | Completed | Pennington Biomedical Research Center | 64 | 2014-02-01 | 2019-03-21 |
| Transfer of Genetically Engineered Lymphocytes in Melanoma Patients Dose 1, Dose 2, Dose 3 - Melanoma | Phase 1 | Active not recruiting | Loyola University | 14 | 2012-07-01 | 2020-10-30 |
| A Study of Strawberries and Disease Risk Placebo, 10G, 20G - Nutritional and Metabolic Diseases, Inflammation | Not applicable | Completed | Clinical Nutrition Research Center, Illinois Institute of Technology | 29 | 2010-09-15 | 2021-02-12 |
Renal Insufficiency (2) · Charcot-Marie-Tooth Disease (1) · Hyperglycemia (1) · Inflammation (1) · Insulin Resistance (1) · Melanoma (1) · Metabolic Syndrome (1) · Nutritional and Metabolic Diseases (1) · Obesity (1) · Pain, Postoperative (1) · Tobacco Smoking (1) · Tobacco Use (1) · Tobacco Use Cessation (1) · Tobacco Use Disorder (1) · Vitamin D Deficiency (1)
AstraZeneca (4) · Clinical Nutrition Research Center, Illinois Institute of Technology (1) · Etern Therapeutics Wuxi Limited (1) · Hangzhou Sciwind Biosciences Co., Ltd. (1) · Loyola University (1) · Pennington Biomedical Research Center (1) · Pharnext S.C.A. (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · University of Leeds (1) · University of Minnesota (1) · University of Southern Denmark (1) · University of Utah (1)
United States (10) · China (3) · United Kingdom (2) · Belgium (1) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Netherlands (1) · Spain (1)
Britt Burton-Freeman, PhD, MS (1) · Chelsey Schlechter, MPH, PhD (1) · Fadi Saba, M.D. (1) · Florian Thomas, MD (1) · Gary Williamson (1) · Hilda Nyambe (1) · Indika Edirisinghe, PhD (1) · Jack Puymirat, MD (1) · Jennifer C Rood, Ph.D. (1) · Jicheng Lv, Doctor (1) · Joel M Neutel, M.D. (1) · Kevin A Peterson, MD, MPH (1) · Kwabena Ayesu, M.D. (1) · Marianne De Visser, MD (1)
PMID 25491744, PMID 25519680, PMID 26070802, PMID 26842771, PMID 27387831, PMID 29021286, PMID 30650121, PMID 38047142
2015 (1), P01CA154778 (1), P50AT002776 (1), R44CA126461 (1), U54CA280812 (1)